cisplatin + docetaxel + zoledronic acid

This is a combination therapy consisting of cisplatin (a platinum-based chemotherapeutic agent), docetaxel (a taxane chemotherapeutic agent), and zoledronic acid (a nitrogen-containing bisphosphonate). The combination has been studied primarily for the treatment of non-small cell lung cancer (NSCLC) patients with bone metastases. Clinical studies have shown that this combination is well-tolerated with acceptable renal toxicity and has modest activity as a first-line treatment for NSCLC patients with bone metastases. The combination has demonstrated improvement in pain scores in 77% of patients after six weeks of treatment.